NCT01678976View on ClinicalTrials.gov

Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2002

Primary Completion Date

April 30, 2002

Study Completion Date

April 30, 2002

Conditions

Epilepsy

Interventions

DRUG

BIA 2-093

Tablets containing BIA 2-093 in doses of 300 and 600 mg

DRUG

Oxcarbazepine

Tablets containing 300 mg and 600 mg of Trileptal®

Trial Locations (1)

4745-457

BIAL - Portela & Cª - Human Pharmacology Unit (UFH), S. Mamede Do Coronado

All Listed Sponsors

lead

Bial - Portela C S.A.

INDUSTRY

NCT01678976 - Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers | Biotech Hunter | Biotech Hunter